Edwards Lifesciences Corp. (EW) has seen significant market activity as it has
consistently outperformed its competitors despite getting mixed results. Key financial institutions like
Citigroup maintain a 'Buy' recommendation and
Barclays has increased EW's price target to $101.00. These positive quick assessments follow a strong Q1 2024 earnings call, where the company reported
robust full-year 2023 financial results. EW’s shares have risen by 21.8% YTD, and the company plans to
spin-off its Critical Care Unit in 2024, a strategic move that might further improve its performance. Possible threats to the company's performance were also mentioned, including an addition to the company's risk profile and the company's
stock underperforming on specific days. Despite these shaky moments, the company's
sales growth and strategic plans have excited analysts who have, as a result, lifted their price targets for EW’s stocks.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Fri, 10 May 2024 00:53:45 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor 5
